Sanofi Completes Dosing in Phase 1 Trial of 'Dupixent' Utilizing Alteogen's Technology
Sanofi's 'Dupixent' (ingredient: dupilumab), which utilizes Alteogen's subcutaneous (SC) injection platform technology, has completed dosing for participants in its phase 1 clinical trial.
Exterior view of Alteogen headquarters and research center in Yuseong-gu, Daejeon. Alteogen
View original imageAccording to the clinical information site ClinicalTrials on July 23, Sanofi plans to complete its phase 1 clinical trial of Dupixent, administered in combination with Alteogen's hyaluronidase 'ALT-B4' (ingredient: verahyaluronidase alpha), by September.
This phase 1 trial, which began in June, was conducted on 40 healthy adult participants. The purpose of the trial is to evaluate the pharmacokinetics (PK), safety, and anti-drug antibodies (ADA) following the co-administration of Dupixent and ALT-B4.
Hot Picks Today
Karina Fetches 6.7 Billion Won, Lives Under 24-Hour Armed Guard... World's Most Expensive Cow in the Spotlight
- "If It Breaks, That's It": Chaos Among Samsung and SK hynix Consumers... Soaring SSD Prices Mean "No Replacement, Only Refund at Original Price"
- "I'll Pay with Both Shares and Cash" vs "Cash Only"... Why Chey Taewon Filed a Further Appeal After Careful Deliberation
- Yu In-chon: "Even Sadder Than Last Year"...Bicycle Pilgrimage to Mark Brother's First Anniversary
- Do Night Runners Need Sunscreen? MFDS Says "UV from Streetlights Has Minimal Impact"
The ALT-B4 used in this trial is a recombinant human hyaluronidase enzyme developed by Alteogen, enabling the subcutaneous injection of large-volume drugs and facilitating their absorption in the body. Sanofi is utilizing Alteogen's technology to develop a new formulation of Dupixent aimed at improving dosing convenience.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
